As Fillit noted, GLP-1 drugs would be very good candidates to be delivered in combination with an anti-amyloid drug like Eisai and Biogens recently approved Leqembi (lecanemab) or Lillys investigational donanemab, because there is no overlap in the mechanism of action
Patients may also experience some mild side effects, such as nausea, gastrointestinal symptoms like diarrhea or constipation, and headaches
If youre living with migraine, its natural to wonder if these medications could affect your condition
There are several overlapping reasons: Food stays in the stomach longer, which can extend fullness
Research published in Nutrients (2023) and updated clinical reviews in early 2025 demonstrate that these SCFAs act as chemical keys that unlock the L-cells in your colon, directly triggering the release of GLP-1 into your bloodstream